Druggable drivers of lung cancer

Oncotarget

Volumn 4, Issue 9, 2013, Pages 1334-1335

  Fawdar, Shameem ^a   Edwards, Zoe C ^a   Brognard, John ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; VASCULOTROPIN INHIBITOR;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECT; EDITORIAL; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE FREQUENCY; HUMAN; LOSS OF FUNCTION MUTATION; LUNG CANCER; MELANOMA; SIGNAL TRANSDUCTION;

DISEASE-FREE SURVIVAL; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84884683574     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1223     Document Type: Editorial

References (8)

1. Gazdar AF. Cancer Metastasis Rev. 2010; 29(1):37-48.
2. Chapman PB et al. N Engl J Med. 2010; 364(26):2507-2516.
3. Kim E et al. Cancer Discovery. 2011.
4. Fawdar S et al. Proc National Academy of Sciences. 2013.
5. Greenman C et al. Nature. 2007; 446(7132):153-158.
6. Imielinski M et al. Cell . 2012; 150(6):1107-1120.
7. Gerber DE, Minna JD. Cancer Cel. 2010; 118(6):548-551.
8. Brognard J. Cancer research 71(8):3152-3161.